Nebenwirkungen · Alimta
ALIMTA 100 mg powder for concentrate for solution for infusion ALIMTA 500 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 8
HOS-113248 · Präparat HOS-093893
The most commonly reported undesirable effects related to pemetrexed, whether used as monotherapy or in combination, are bone marrow suppression manifested as anaemia, neutropenia, leukopenia, thrombocytopenia; and gastrointestinal toxicities, manifested as anorexia, nausea, vomiting, diarrhoea, constipation, pharyngitis, mucositis, and stomatitis. Other undesirable effects include renal toxicities, increased aminotransferases, alopecia, fatigue, dehydration, rash, infection/sepsis and neuropathy. Rarely seen events include Stevens-Johnson syndrome and toxic epidermal necrolysis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-16T09:15:00Z · SHA-256 24fa9a3eaa82090ed2a3ef46878f3aa590ff176bacda3ce9480b2122b62961a9 · Passage 191fd326546af44335a5f88a2190c9ed9dc1b4dbf7b0f9eb860f9eeaf677683e · Zeichen 31–617 im Abschnitt